Dilemma of Managing Asymptomatic Children Referred with 'culture-confirmed' Drug-resistant Tuberculosis
Overview
Affiliations
Background: The diagnosis of drug-resistant tuberculosis (DR-TB) in children is challenging and treatment is associated with many adverse effects.
Objective: We aimed to assess if careful observation, without initiation of second-line treatment, is safe in asymptomatic children referred with 'culture-confirmed' DR-TB.
Setting: KwaZulu-Natal, South Africa-an area with high burdens of HIV, TB and DR-TB.
Design, Intervention And Main Outcome Measures: We performed an outcome review of children with 'culture-confirmed' DR-TB who were not initiated on second-line TB treatment, as they were asymptomatic with normal chest radiographs on examination at our specialist referral hospital. Children were followed up every other month for the first year, with a final outcome assessment at the end of the study.
Results: In total, 43 asymptomatic children with normal chest radiographs were reviewed. The median length of follow-up until final evaluation was 549 days (IQR 259-722 days); most (34; 83%) children were HIV uninfected. Resistance patterns included 9 (21%) monoresistant and 34 (79%) multidrug-resistant (MDR) strains. Fifteen children (35%) had been treated with first-line TB treatment, prior to presentation at our referral hospital. At the final evaluation, 34 (80%) children were well, 7 (16%) were lost to follow-up, 1 (2%) received MDR-TB treatment and 1 (2%) died of unknown causes. The child who received MDR-TB treatment developed new symptoms at the 12-month review and responded well to second-line treatment.
Conclusions: Bacteriological evaluation should not be performed in the absence of any clinical indication. If drug-resistant Mycobacterium tuberculosis is detected in an asymptomatic child with a normal chest radiograph, close observation may be an appropriate strategy, especially in settings where potential laboratory error and poor record keeping are constant challenges.
Teo A, MacLean E, Fox G Eur Respir Rev. 2024; 33(172).
PMID: 38719737 PMC: 11078153. DOI: 10.1183/16000617.0208-2023.
Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children.
Turkova A, Wills G, Wobudeya E, Chabala C, Palmer M, Kinikar A N Engl J Med. 2022; 386(10):911-922.
PMID: 35263517 PMC: 7612496. DOI: 10.1056/NEJMoa2104535.
XDR-TB Transmitted from Mother to 10-Month-Old Infant: Diagnostic and Therapeutic Problems.
Kozinska M, Bogucka K, Kedziora K, Szpak-Szpakowska J, Pedzierska-Olizarowicz W, Pustkowski A Diagnostics (Basel). 2022; 12(2).
PMID: 35204528 PMC: 8871013. DOI: 10.3390/diagnostics12020438.
Tuberculosis susceptibility and protection in children.
Roy R, Whittaker E, Seddon J, Kampmann B Lancet Infect Dis. 2018; 19(3):e96-e108.
PMID: 30322790 PMC: 6464092. DOI: 10.1016/S1473-3099(18)30157-9.
Martinez L, Shen Y, Handel A, Chakraburty S, Stein C, Malone L Lancet Respir Med. 2017; 6(4):276-286.
PMID: 29273539 PMC: 5876110. DOI: 10.1016/S2213-2600(17)30497-6.